

DEC 09 2002

Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2132.040APPLICATION NO.
09/845,738INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
JACKOWSKI et al.FILING DATE
04/30/01GROUP
1641

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
L/C	5,538,897	07/96	Yates, III et al.	436	89	3/14/94
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
L/C	WO 87/06344	10/87	PCT	G01N	33/53	X
	WO 91/13352	09/91	PCT	G01N	33/48	X
	WO 98/32390	07/98	PCT	A61B	19/00	X
	WO 01/05422	01/01	PCT ①	A61K	38/17	X
L/C	WO 00/49410	08/00	PCT	G01N	33/53	X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

L/C		Tang, et al., "Contribution of Renal Secreted Completed C3 to the Circulating Pool in Humans", Journal of Immunology (1999), Vol. 162, No. 7, pp. 4336-4341.
		Koch, et al., "A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody", Immunogenetics (1986), Vol. 23, No. 5, pp. 322-325.
		Muscari, et al., "Association of Serum C3 Levels With the Risk of Myocardial Infarction", American Journal of Medicine (1995), Vol. 98, No. 4, pp. 357-364.
L/C		Harrison et al., "Structure of C3f, a Small Peptide Specifically Released during Inactivation of the Third Component of Complement", Component (1988), Vol. 5, No. 1, pp. 27-32.

EXAMINER

Olivia. X Cook

DATE CONSIDERED

9/2/03

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

① only English abstract considered
L/C COOK 9/2/03.

RECEIVED

DEC 11 2002

TECH CENTER 1600/2900

